首页> 外文期刊>Acta ophthalmologica Scandinavica >Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn
【24h】

Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn

机译:局部应用贝伐单抗的安全性,渗透性和功效:化学灼伤后眼药水在角膜新生血管形成中的评估

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: That vascular endothelial growth factor (VEGF) plays a major role in inflammatory angiogenesis has been well established. This pilot study was designed to evaluate experimental treatment with bevacizumab eyedrops in corneal neovascularization induced by alkali burn. The feasibility of topical administration, corneal cell viability and corneal penetration were investigated in an animal model. Methods: Eighteen chinchilla bastard rabbit corneas injured with 1 m NaOH were divided into three groups: untreated, early and late treatment groups. Eyedrops of bevacizumab solution (25 mg/ml) were administered five times daily. Clinical examination under stereoscopic microscope was performed to evaluate corneal opacity, neovascularization, vessel size and oedema. Histopathology was analysed for vessel density and apoptotic reaction. Additionally, intracameral bevacizumab concentration was measured with enzyme-linked immunosorbent assay (ELISA) after repeated topical applications.Results: A fast increase in aqueous bevacizumab concentration was achieved when the solution was instilled every minute onto a healthy eye surface. As well as clear anti-angiogenic effects, anti-fibrotic effects were also seen after corneal burn, maintaining corneal transparency. Early treatment of actively growing vessels showed a significantly better outcome, although apoptosis of pre-existing vessels could also be induced by the late treatment. No specific toxicity was seen regarding epithelium, keratocytes or endothelium.Conclusions: The data from this pilot study suggest that bevacizumab eyedrops can sufficiently penetrate the corneal stroma and anterior chamber. When administered soon after alkali burn, bevacizumab seems to significantly reduce corneal damage. Combinations of established treatment regimens with topical bevacizumab might be considered in severe injuries with otherwise devastating prognoses.
机译:目的:血管内皮生长因子(VEGF)在炎症性血管生成中起主要作用已得到公认。这项初步研究旨在评估贝伐单抗滴眼液在碱烧伤诱导的角膜新生血管形成中的实验性治疗。在动物模型中研究了局部给药,角膜细胞活力和角膜渗透的可行性。方法:将18只1m NaOH伤害的栗鼠混种兔角膜分为三组:未治疗组,早期和晚期治疗组。贝伐单抗溶液滴眼液(25 mg / ml)每天给药五次。在立体显微镜下进行临床检查以评估角膜混浊,新血管形成,血管大小和水肿。分析组织病理学的血管密度和凋亡反应。此外,重复局部应用后,通过酶联免疫吸附测定(ELISA)测定了前房贝伐单抗的浓度。结果:将溶液每分钟滴入健康的眼睛表面后,贝伐单抗的水溶液浓度快速增加。除明显的抗血管生成作用外,在角膜烧伤后还观察到抗纤维化作用,保持了角膜透明性。早期治疗活跃的血管显示出明显更好的结局,尽管晚期治疗也可以诱导已有血管的凋亡。结论:这项初步研究的数据表明,贝伐单抗滴眼液可以充分穿透角膜基质和前房,因此对上皮,角质形成细胞或内皮没有特异性毒性。当碱烧伤后不久给药时,贝伐单抗似乎可以显着减少角膜损伤。在严重受伤且预后极差的情况下,可以考虑将既定的治疗方案与局部贝伐单抗联合使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号